Author/Authors :
Hosseini, Azar Pharmacological Research Center of Medicinal Plants - Mashhad University of Medical Sciences, Mashhad, Iran - Department of Pharmacology - Faculty of Medicine - Mashhad University of Medical Sciences, Mashhad, Iran , Rajabian, Arezoo Department of Internal Medicine - Faculty of Medicine - Mashhad University of Medical Sciences, Mashhad, Iran , Forouzanfar, Fatemeh Neuroscience Research Center - Mashhad University of Medical Sciences, Mashhad, Iran - Department of Neuroscience - Faculty of Medicine - Mashhad University of Medical Sciences, Mashhad, Iran , Farzadnia, Mahdi Cancer Molecular Pathology Research Center - Imam Reza Hospital - Faculty of Medicine - Mashhad University of Medical Sciences, Mashhad, Iran , Boroushaki, Mohammad Taher Pharmacological Research Center of Medicinal Plants - Mashhad University of Medical Sciences, Mashhad, Iran - Department of Pharmacology - Faculty of Medicine - Mashhad University of Medical Sciences, Mashhad, Iran
Abstract :
Objective: The clinical use of tacrolimus is limited due to its side effects. This research investigated the protective activities of pomegranate seed oil (PSO) against TAC toxicity.
Materials and Methods: The groups are included normal (1 ml of corn oil), TAC (2 mg/kg), and co-treatment of PSO (0.4 and 0.8 ml/kg) and TAC. All administrations were carried out intraperitoneally for 14 days. After the last injection, blood was collected from the heart.
Results: TAC increased creatinine and urea. Increased malondialdehyde, reduced thiol content and superoxide dismutase. The elevation of lactate dehydrogenase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine kinase-MB and creatinine phosphokinase that confirmed cardiac toxicity. PSO reduced TAC toxicity. PSO decreased TAC-induced pathology injury.
Conclusion: PSO reduced TAC toxicity in renal and heart via scavenging free radicals.
Keywords :
Pomegranate seed oil , Tacrolimus , Nephrotoxicity , Cardiotoxicity
